ACADIA combines monopoly-like NUPLAZID and DAYBUE cash flows with a 2038 patent runway and high-value remlifanserin optionality, supporting substantial asymmetric upside.
Overview
ACADIA is a commercial-stage CNS and neuro-rare biopharmaceutical company whose revenue is generated entirely by NUPLAZID and DAYBUE. NUPLAZID is the sole FDA-approved treatment for Parkinson’s disease psychosis, while DAYBUE is the first and only approved Rett syndrome therapy, giving the portfolio unusually strong competitive positioning and pricing power. **Q2 2026 demonstrated durable execution:** GAAP revenue rose 16.4% year over year to $308 million, net income increased to $32 million, and diluted EPS reached $0.18 versus $0.16 a year earlier. NUPLAZID sales were $183 million, up 8.9%, and DAYBUE sales were $125 million, up 30.2%. Management raised FY 2026 revenue guidance to $1.24–$1.30 billion and DAYBUE guidance to $480–$510 million. DAYBUE STIX, European expansion, Japan development, and the February field-force expansion support the commercial trajectory. **The valuation case combines a patent runway toward 2038, zero debt, $956 million of cash and investments, and remlifanserin optionality.** At $28.02, the report’s probability-weighted five-year value is $57.36, although near-term volatility will be driven by the September–October 2026 clinical readout.